PL3507287T3 - Podstawione n-[2-(4-fenoksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)-etylo]benzamidowe i n-[2-(4-benzyloksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)etylo]benzamidowe pochodne antagonistów receptora p2x7 - Google Patents

Podstawione n-[2-(4-fenoksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)-etylo]benzamidowe i n-[2-(4-benzyloksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)etylo]benzamidowe pochodne antagonistów receptora p2x7

Info

Publication number
PL3507287T3
PL3507287T3 PL17755110T PL17755110T PL3507287T3 PL 3507287 T3 PL3507287 T3 PL 3507287T3 PL 17755110 T PL17755110 T PL 17755110T PL 17755110 T PL17755110 T PL 17755110T PL 3507287 T3 PL3507287 T3 PL 3507287T3
Authority
PL
Poland
Prior art keywords
thiazol
ethyl
benzamide
benzyloxypiperidin
phenoxypiperidin
Prior art date
Application number
PL17755110T
Other languages
English (en)
Inventor
Paolo Pevarello
Adolfo Prandi
Original Assignee
Axxam S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxam S.P.A. filed Critical Axxam S.P.A.
Publication of PL3507287T3 publication Critical patent/PL3507287T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL17755110T 2016-08-31 2017-08-09 Podstawione n-[2-(4-fenoksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)-etylo]benzamidowe i n-[2-(4-benzyloksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)etylo]benzamidowe pochodne antagonistów receptora p2x7 PL3507287T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16186655.3A EP3290416A1 (en) 2016-08-31 2016-08-31 Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist
PCT/EP2017/070163 WO2018041563A1 (en) 2016-08-31 2017-08-09 Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives p2x7 receptor antagonists
EP17755110.8A EP3507287B1 (en) 2016-08-31 2017-08-09 Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives p2x7 receptor antagonists

Publications (1)

Publication Number Publication Date
PL3507287T3 true PL3507287T3 (pl) 2020-12-28

Family

ID=56852153

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17755110T PL3507287T3 (pl) 2016-08-31 2017-08-09 Podstawione n-[2-(4-fenoksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)-etylo]benzamidowe i n-[2-(4-benzyloksypiperydyn-1-ylo)-2-(1,3-tiazol-5-ilo)etylo]benzamidowe pochodne antagonistów receptora p2x7

Country Status (14)

Country Link
US (1) US10669267B2 (pl)
EP (2) EP3290416A1 (pl)
JP (1) JP6957595B2 (pl)
CN (1) CN109689650B (pl)
CA (1) CA3031354C (pl)
DK (1) DK3507287T3 (pl)
ES (1) ES2816204T3 (pl)
HU (1) HUE050040T2 (pl)
IL (1) IL264708B (pl)
PL (1) PL3507287T3 (pl)
PT (1) PT3507287T (pl)
RU (1) RU2755705C2 (pl)
SI (1) SI3507287T1 (pl)
WO (1) WO2018041563A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4015039A1 (en) 2020-12-18 2022-06-22 AXXAM S.p.A. Heterocyclic derivatives as p2x7 receptor antagonists
AU2024400853A1 (en) 2023-12-15 2026-05-28 Ishihara Sangyo Kaisha, Ltd. N-substituted oxy-2-aminothiazolecarboxamide compound or salt thereof and agricultural and horticultural fungicide
CN121159455A (zh) * 2024-06-18 2025-12-19 武汉人福创新药物研发中心有限公司 氨基酯类化合物及其作为p2x7拮抗剂的用途
WO2026041663A1 (en) 2024-08-22 2026-02-26 Breye Therapeutics Aps P2x7 receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
EP1626962B1 (en) 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
JP5369173B2 (ja) 2008-04-22 2013-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン若しくはイソキノリン置換ｐ２ｘ７アンタゴニスト
KR102232742B1 (ko) * 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
JP6285736B2 (ja) 2014-02-04 2018-02-28 株式会社ソニー・インタラクティブエンタテインメント 情報処理装置および入力デバイスの割当方法
EP2905282A1 (en) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists

Also Published As

Publication number Publication date
CA3031354A1 (en) 2018-03-08
SI3507287T1 (sl) 2020-09-30
HUE050040T2 (hu) 2020-11-30
RU2755705C2 (ru) 2021-09-20
EP3290416A1 (en) 2018-03-07
CA3031354C (en) 2025-05-06
DK3507287T3 (da) 2020-08-24
IL264708B (en) 2021-04-29
US10669267B2 (en) 2020-06-02
RU2019106209A (ru) 2020-10-01
ES2816204T3 (es) 2021-03-31
CN109689650B (zh) 2022-11-25
US20190194180A1 (en) 2019-06-27
JP6957595B2 (ja) 2021-11-02
PT3507287T (pt) 2020-09-04
EP3507287A1 (en) 2019-07-10
RU2019106209A3 (pl) 2020-10-01
JP2019524750A (ja) 2019-09-05
WO2018041563A1 (en) 2018-03-08
EP3507287B1 (en) 2020-07-15
CN109689650A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
IL269065A (en) Paranoid X receptor agonists and uses thereof
EP3181559B8 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
IL269068A (en) Paranoid X receptor agonists and uses thereof
MA44007A (fr) Inhibiteurs du récepteur interagissant avec protéine kinase 1
IL326957A (en) Mrgprx2 antagonists and their uses
IL281471A (en) Farnesoid x receptor agonists and uses thereof
HUE064609T2 (hu) Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
IL281474A (en) Farnesoid x receptor agonists and uses thereof
SG11202102651SA (en) Farnesoid x receptor agonists and uses thereof
IL255937B (en) Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists
ZA201804387B (en) Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
IL285025A (en) History of heterocyclic carboxamides, their preparation and use
IL292693B1 (en) Mrgprx2 antagonists and their uses
IL277144A (en) Adenosine receptor antagonists and uses thereof
PL3317272T3 (pl) Chwastobójczo skuteczne pochodne N-(1,3,4-oksadiazol-2-ilo)arylokarboksyamidowe
HUE050040T2 (hu) Szubsztituált n-[2-(4-fenoxipiperidin-1-il)-2-(1,3-tiazol-5-il)etil]benzamid és n-[2-(4-benziloxipiperidin-1-il)-2-(1,3-tiazol-5-il)etil]benzamid származékok mint P2X7 receptor antagonisták
GB202018729D0 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
PT3609868T (pt) Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7
IL270275B1 (en) Heterocyclic p2x7 antagonists
ZA202401526B (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
SG11202010985TA (en) Heterocyclic derivatives and use thereof
EP3760620A4 (en) PRESCRIBER ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
SG11202100027RA (en) Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid